Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
26.10.2022 - Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patientsBERKELEY HEIGHTS, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) - Cyclacel Pharmaceuticals, Inc. (NASDAQ: ... Seite 1
Source: wallstreet-online.de